← Back to Clinical Trials
Recruiting NCT06406933

NCT06406933 Salivary Conductivity Screening for Dry Eye Disease and Sjögren's Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06406933
Status Recruiting
Phase
Sponsor Chang Gung Memorial Hospital
Condition Sjogren's Syndrome
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2023-07-01
Primary Completion 2025-12-31

Trial Parameters

Condition Sjogren's Syndrome
Sponsor Chang Gung Memorial Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 20 Years
Max Age 80 Years
Start Date 2023-07-01
Completion 2025-12-31
Interventions
Carbomer Gel/Jelly

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Dry eye disease, or keratoconjunctivitis sicca, is one of the most common diseases encountered at ophthalmologic clinics. Patient with dry eye disease commonly presented foreign body sensation, red eye, blurred vision, etc. Numerous treatments for dry eye disease are proposed due to its multifactorial etiology. Sjögren syndrome, which is one of the main etiologies of dry eye disease, is an autoimmune disease characterized by dysfunction of lacrimal and salivary glands. Although dry eye status can be easily examined by ocular surface staining, the methods quantifying salivary flow rate are hard to performed clinically, such as salivary gland scintigraphy and sialometry. Furthermore, disease activity could only rely on serum markers or salivary gland ultrasound. Recently, a portable device measuring salivary conductivity is believed to assess fluid status and renal function. Interestingly, the composition of salivary electrolytes in patients with Sjögren syndrome is different from those with other causes of hyposalivation. Thus, this study aims to evaluate whether salivary conductivity in combination with ocular surface staining can be a non-invasive diagnostic test for primary Sjögren syndrome among people with dry eye disease.

Eligibility Criteria

Inclusion Criteria: 1. Adults aged 20 and older 2. Patients with normal and dry eye syndrome Exclusion Criteria: 1. Hepatitis C 2. Acquired immunodeficiency syndrome 3. Lymphoma 4. Intestinal amyloidosis 5. Open pulmonary tuberculosis 6. Graft-versus-host disease 7. Rheumatoid or lupus erythematosus and other autoimmune diseases 8. IgG4-related diseases 9. Head and neck radiation therapy 10. Glaucoma 11. History of infectious keratitis 12. History of ophthalmic surgery 13. Wear contact lenses in the month before the trial 14. Chew betel nuts or smoke within one month before the trial

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology